Aptivus and Selzentry

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Coadministration with tipranavir/ritonavir does not appear to significantly alter the plasma concentrations of maraviroc. In 12 study subjects, coadministration of maraviroc (150 mg twice a day) with tipranavir/ritonavir (500 mg/200 mg twice a day) reduced the peak plasma concentration (Cmax) of maraviroc by 14% and increased the trough plasma concentration (Cmin) by 80%, but had no effect on the overall systemic exposure. No dosage adjustment of maraviroc is necessary when coadministered with tipranavir/ritonavir in the absence of concomitant potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, delavirdine, clarithromycin, telithromycin, or nefazodone.

Aptivus

Generic Name: tipranavir

Brand name: Aptivus

Synonyms: n.a.

What is Aptivus?

Selzentry

Generic Name: maraviroc

Brand name: Selzentry

Synonyms: n.a.

What is Selzentry?